Stock futures turned lower Wednesday as inflation advanced in August largely because of a jump in gas prices.
These stocks were poised to make moves Wednesday:
(ticker: AAPL) was up 0.6%, a day after declining 1.7% following the release of its new iPhone lineup. While some analysts had expected price increases across the Pro lineup,
only increased the starting price of its iPhone 15 Pro Max phone by $10.
U.S.-listed shares of
(BP) rose 1.4% in premarket trading after Chief Executive Bernard Looney resigned amid an investigation into new allegations of his personal relationships with colleagues. Looney had pushed for the oil giant’s transition to clean energy.
(F) was rising 1.5% to $12.64, and
(GM) gained 0.3% to $33.67.
initiated coverage of Ford with a Buy rating and price target of $15, while the analysts upgraded General Motors to Buy from Neutral and raised the price target to $44 from $41. The upgrades come as the United Auto Workers and the “Detroit Three” auto makers, including
(STLA), are running out of time to negotiate a new labor contract before the deadline of Thursday at 11:59 p.m. UBS said four weeks of a strike at each of the auto makers has been priced in.
(MRNA) rose 6.8% after the vaccine maker released positive results from a late-stage trial of an mRNA flu vaccine and noted strides made in investigational treatments for cancer and latent, rare, and infectious diseases.
(SAVE) fell 4.4% after the airline reduced its third-quarter guidance, citing higher fuel prices and an increase in discounted flights booked through the pre-Thanksgiving travel window.
(AAL) slid 3.3% also after cutting guidance, prompted by higher labor costs following its pay agreement with pilots and elevated fuel prices. Other airline stocks also fell, with
Delta Air Lines
(DAL) down 2.4% and
(LUV) off 2.2%.
American depositary receipts of
) declined 2.6%,
(XPEV) was down 3%, and
(LI) fell 1.7% after European Commission President Ursula von der Leyen said an anti-subsidy investigation would be launched into Chinese electric-vehicle makers.
(TSLA), which holds a sizable share of the European EV market, rose 0.7%.
(RCKT) jumped 38% after the pharmaceutical company said it reached alignment with the Food and Drug Administration regarding its global Phase 2 trial for a treatment of Danon disease, a fatal genetic cardiac disease.
Write to Joe Woelfel at firstname.lastname@example.org